Syntara (SNT) Investor presentation summary

Investment profile

• Australian-founded clinical-stage developer with three Phase 2 studies in blood cancer indications and an addressable market >US$4.5bn; pipeline spans blood cancers, fibrosis and neurodegeneration.

• Pro forma cash A$18.2m at 30 Jun 2026; funded into FY28; A$4.7m R&D tax incentive received Sep 2026.

• Market cap A$49.1m and enterprise value A$30.9m as of 9 Oct 2026; institutional ownership >44%.

• A$11.5m in non-dilutive grant funding awarded in the prior 3 years; specialist healthcare investors and a team with licensing experience.

Amsulostat and myelofibrosis

• Positive 52-week topline data from a Phase 2 blood cancer trial; safety and tolerability, with clinical benefit increasing in size and durability beyond 24 weeks, compared favourably with drugs in development.

• FDA IND and orphan drug designation in myelofibrosis; pan-LOX inhibitor positioned for potential disease modification and combination use with standard of care.

• Phase 2a suboptimal MF study reported TSS50 73% (8/11), SVR25 44% (4/9) and SVR35 33% (3/9) at W24 and beyond; spleen results used patients with baseline SV ≥450mL and >80% ruxolitinib compliance.

• Planned BRIDGE-MF Phase 2b is double-blind, placebo-controlled and randomized 2:1; primary endpoint TSS50 at W36; Q4 2026 start, 18-month recruitment, 9-month treatment and US$20–25m budget.

• JAK inhibitors have dose-limiting tolerability issues; 75% discontinuation at 5 years and median overall survival of 14–16 months after discontinuation.

Other pipeline assets

• SNT-4728 is a brain-penetrant dual SSAO and MAO-B inhibitor; 20 of 30 active-treatment patients had reduced brain inflammation after 12 weeks, with a significant right-putamen change (p=0.0145).

• SNT-4728 showed a between-group MDS-UPDRS Part III difference at W24 (p=0.021); scores decreased in the active arm after treatment cessation and increased in the placebo group.

• More than 70% of iRBD patients may develop Parkinson’s or related disorders; no approved iRBD treatment was described.

• Global scar-treatment market projected at US$50–55bn by 2030; no FDA-approved scar therapies; LOX inhibition targets matrix stiffness.

• Prior topical pan-LOX Phase 1 study found a mean collagen reduction of 30% versus placebo after 3 months (p<0.01), with improved scar vascularization.

• SNT-9465 Phase 1b uses a randomized, double-blind, placebo-controlled split-scar design in 20 adults with hypertrophic sternotomy scars; endpoints include safety, PK/PD and scar imaging measures.